Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
A. Lecube, C. Hernández, J. Genescà, R. Simó.
Glucose abnormalities in patients with hepatitis C virus infection: Epidemio logy and pathogenesis.
Diabetes Care, 29 (2006), pp. 1 140-1149
[2.]
R. Simó, C. Hernández, J. Genescà, R. Jardí, J. Mesa.
High prevalence of hepatitis C virus infection in diabetic patients.
Diabetes Care, 19 (1996), pp. 998-1000
[3.]
S. Rudoni, J.M. Petit, J.B. Bour, L.S. Aho, A. Castaneda, G. Vaillant, et al.
HCV infection and diabetes mellitus: influence of the use of finger stick devices on nosocomial transmission.
Diabetes Metab, 25 (1999), pp. 502-505
[4.]
A.L. Mason, J.Y. Lau, N. Hoang, K. Qian, G.J. Alexander, L. Xu, et al.
Association of diabetes mellitus and chronic hepatitis C virus infection.
Hepatology, 29 (1999), pp. 328-333
[5.]
V. Okan, M. Araz, S. Aktaran, T. Karsligil, I. Meram, Z. Bayraktaroglu, et al.
Increased frequency of HCV but not HBV infection in type 2 diabetic patients in Turkey.
Int J Clin Pract, 56 (2002), pp. 175-177
[6.]
H.F. Chen, C.Y. Li, P. Chen, T.T. See, H.Y. Lee.
Seroprevalence of hepatitis B and C in type 2 diabetic patients.
J Chin Med Assoc, 69 (2006), pp. 146-152
[7.]
E. Özylilkan, M. Arslan.
Increased prevalence of diabetes mellitus mellitus in patients with chronic hepatitis C virus infection.
Am J Gastroenterol, 91 (1996), pp. 1480-1481
[8.]
A. Lecube, C. Hernández, J. Genescà, J.I. Esteban, R. Jardí, R. Simó.
High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury.
Diabetes Care, 27 (2004), pp. 1171-1175
[9.]
S.H. Mehta, F.L. Brancati, M.S. Sulkowski, S.A. Strathdee, M. Szklo, D.L. Thomas.
Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States.
Ann Intern Med, 133 (2000), pp. 592-599
[10.]
S. Boluda Monzo, J. Mesa Manteca, G. Obiols Alfonso, R. Simó Canonge.
Antígeno de superficie de la hepatitis B en la diabetes mellitus.
Med Clin (Barc), 92 (1989), pp. 397
[11.]
M.C. Honeyman, N.L. Stone, L.C. Harrison.
T-cell epitopes in type 1 diabetes mellitus autoantigen tyrosine phosphatase IA2: potential for mimicry with rotavirus and other envirommental agents.
Mol Med, 4 (1998), pp. 231-239
[12.]
S.H. Mehta, F.L. Brancati, M.S. Sulkowski, S.A. Strathdee, M. Szklo, D.L. Thomas.
Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States.
Hepatology, 33 (2001), pp. 1554
[13.]
C. Betterle, P. Fabris, R. Zanchetta, B. Pedini, G. Tositti, E. Bosi, et al.
Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection.
Diabetes Care, 23 (2000), pp. 1177-1181
[14.]
S. Piquer, C. Hernández, J. Enriquez, A. Ross, J.I. Esteban, J. Genescà, et al.
Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: effect of treatment with interferon.
J Lab Clin Med, 137 (2001), pp. 38-42
[15.]
M. Masini, D. Campani, U. Boggi, M. Menicagli, N. Funel, M. Pollera, et al.
Hepatitis C virus infection and human pancreatic beta-cell dysfunction.
Diabetes Care, 28 (2005), pp. 940-941
[16.]
A. Lecube, C. Hernández, J. Genescà, R. Simó.
Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study.
Diabetes Care, 29 (2006), pp. 1096-1101
[17.]
M.H. Mendler, B. Turlin, R. Moirand, A.M. Jouanolle, T. Sapey, D. Guyader, et al.
Insulin resistance-associated hepatic iron overload.
Gastroenterology, 117 (1999), pp. 1155-1163
[18.]
A. Lecube, C. Hernandez, J. Genesca, J.I. Esteban, R. Jardi, L. Garcia, et al.
Diabetes mellitus is the main factor accounting for the high ferritin levels detected in chronic hepatitis C virus infection.
Diabetes Care, 27 (2004), pp. 2669-2675
[19.]
J.M. Petit, J.B. Bour, C. Galland-Jos, A. Minello, B. Verges, M. Guiguet, et al.
Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C.
J Hepatol, 35 (2001), pp. 27983
[20.]
F. Ramalho.
Hepatitis C virus infection and liver steatosis.
Antiviral Res, 60 (2003), pp. 125-127
[21.]
K. Moriya, H. Fujie, Y. Shintani, H. Yotsuyanagi, T. Tsutsumi, K. Ishibashi, et al.
The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice.
Nat Med, 4 (1998), pp. 1065-1067
[22.]
H. Fujie, H. Yotsuyanagi, K. Moriya, Y. Shintani, T. Tsutsumi, T. Takayama, et al.
Steatosis and intrahepatic hepatitis C virus in chronic hepatitis.
J Med Virol, 59 (1999), pp. 141-145
[23.]
G. Waris, D.J. Felmlee, F. Negro, A. Siddiqui.
Hepatitis C virus induces the proteolytic cleavage of sterol regulatory element binding proteins (SREBPs) and stimulates the phosphorilation of SREBPs via oxidative stress.
J Virol, (2007),
[24.]
Y. Shintani, H. Fujie, H. Miyoshi, T. Tsutsumi, K. Tsukamoto, S. Kimura, et al.
Hepatitis C virus infection and diabetes mellitus: direct involvement of the virus in the development of insulin resistance.
Gastroenterology, 126 (2004), pp. 840-848
[25.]
M. Malaguarnera, I. Di Fazio, M.A. Romeo, S. Restuccia, A. Laurino, B.A. Trovato.
Elevation of interleukin 6 levels in patients with chronic hepatitis due to hepatitis C virus.
J Gastroenterol, 32 (1997), pp. 211-215
[26.]
R. Simó, A. Lecube, J. Genescà, J.I. Esteban, C. Hernández.
Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection.
Diabetes Care, 29 (2006), pp. 2462-2466
[27.]
A. Lecube, C. Hernández, R. Simó, J.I. Esteban, J. Genescà.
Glucose abnormalities are an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
Am J Gastroenterol, (2007),
Copyright © 2007. Sociedad Española de Endocrinología y Nutrición